Just one 30-minute infusion, 4 times a year1
VYEPTI is administered as an IV infusion every 3 months1
VYEPTI is approved for 100 mg and 300 mg doses1
100 mg is the recommended dose. Some patients may benefit from the approved 300 mg dose.
VYEPTI can be given at an infusion location or at home
Use the VYEPTI Infusion Locator to help your patients find a convenient location to get their 30-minute VYEPTI treatment.
For details and support on administering VYEPTI, download the guide and watch the short video.
Some patients may have payer-mandated or in-network infusion sites.
VYEPTI demonstrated as well tolerated in clinical trials across years
Adverse reactions occurring in PROMISE-1 and PROMISE-2 pivotal phase 3 trials of over 1,700 patients1
Most common adverse reactions (incidence of ≥2% for VYEPTI and ≥2% greater than placebo)1
VYEPTI 100 mg (n=579) |
VYEPTI 300 mg (n=574) |
Placebo (n=588) |
||||
| Nasophar-yngitis | 6% | 8% | 6% | |||
| Hypersen-sitivity reactions* | 1% | 2% | 0% |
*Hypersensitivity reactions included multiple related adverse event (AE) terms, such as hypersensitivity, pruritus, and flushing/hot flush, that occurred on the day of dosing.
PREVAIL
14% of patients reported at least 1 treatment-emergent AE. The most common study drug-related treatment-emergent AEs were hypersensitivity (3.9%) and fatigue (3.1%) in patients on VYEPTI 300 mg. All other AEs were less than 1%, and 6.3% discontinued study drug.5
Across a 2-year clinical study, infusion-site redness (1 patient), itch (1 patient), constipation (1 patient), and hypertension (1 patient) were minimal (n=128).5
No new safety signals were seen during a 2-year study5
Immunogenicity: In an open-label study with 84 weeks of treatment, 18% (23/128) of patients developed anti-eptinezumab-jjmr antibodies, and 39% (9/23) of those patients developed anti-eptinezumab-jjmr neutralizing antibodies. Formation of antibodies did not affect efficacy or the safety profile of eptinezumab.5
High treatment persistency was demonstrated over 2 years
†In the 2-year PREVAIL study, a total of 118 patients (92.2%) completed the primary treatment phase (week 48), and 101 (78.9%) completed the secondary (week 84); 100 patients (78.1%) remained on VYEPTI 20 weeks after administration of the final study dose (week 104), and 6.3% discontinued study drug due to adverse events.
of patients treated with VYEPTI 300 mg continued to receive treatment5,6†
†In the 2-year PREVAIL study, a total of 118 patients (92.2%) completed the primary treatment phase (week 48), and 101 (78.9%) completed the secondary (week 84); 100 patients (78.1%) remained on VYEPTI 20 weeks after administration of the final study dose (week 104), and 6.3% discontinued study drug due to adverse events.
You are about to leave the VYEPTI website for healthcare professionals
